Vascular access failure (VAF) is a critical problem in patients undergoing hemodialysis (HD). Importantly, VAF impairs the quality of life in patients undergoing HD while imposing high medical costs. A variety of strategies (e.g., endovascular therapy and surgical reconstruction) for treating VAF have been established. However, strategies for preventing VAF are scarce. In this review, we summarized the available literatures regarding the prevention of VAF in patients undergoing HD with a focus on arteriovenous fistulas and arteriovenous grafts. This review proposes the following three aspects for developing strategies for preventing VAF: (i) early identification of risk factors of VAF (e.g., preoperative vascular conditions, age, sex, ethnicity, and clinical backgrounds), (ii) prophylactic drugs to reduce the risk of VAF, and (iii) early VAF detection through monitoring and surveillance of vascular access, particularly at frequent stenotic sites. A few prophylactic drugs may effectively prevent VAF based on the patient's clinical background. A few prophylactic drugs may effectively prevent VAF based on the patient's clinical background; however, currently, there is no strong evidence on the efficacy of these drugs in reducing the incidence of VAF. Thus, additional large, randomized controlled studies are warranted to establish effective strategies for preventing VAF.
Background
HeHemodialysis (HD) is one of major modality of renal replacement therapy (RRT), and approximately 1.5 million patients worldwide have end-stage renal disease (ESRD) and require HD [1] . In addition, vascular access failure (VAF) is becoming a critical problem in the maintenance of HD. Although the pathogenesis of VAF has not been completely elucidated, it has been hypothesized to be caused by enhanced smooth muscle cell migration and proliferation [2, 3] , shear stress generated by turbulent blood flow [4, 5] , excessive mechanical stretching due to a mismatch in elastic properties around the site of anastomosis [6] , and oxidants secreted by activated platelets and inflammatory cells [7] .
In this context, an efficiently functioning vascular access (VA) is crucial for patients undergoing HD.
Regarding the type of vascular access (VA) to be used in HD, the Japanese Society for Dialysis Therapy (JSDT) guidelines state that the arteriovenous fistula (AVF) approach is advantageous compared to AVG owing to its durability, low risk of infection, and reduced need for intervention; however, recently, the focus has slightly shifted toward personalizing the type of VA to be used [8] . The Kidney Diseases Outcomes Quality Initiative (K/DOQI) and European Renal Best Practice (ERBP) Guidelines also promote the AVF approach and discourage the use of catheters [9, 10] . Following this recommendation, the use of the AVF approach increased drastically in the United States (US), with 62.8% of patients undergoing HD in a year, according to the United States Renal Data System (USRDS) data in 2018 [10] . Furthermore, JSDT guidelines recommend that arteriovenous grafts (AVGs) should be the second choice if the patient has no superficial native vessels that can be used for anastomosis in AVFs.
VAF impairs the quality of life of patients with HD and imposes considerable medical costs. For instance, the annual expenditure associated with VA is more than $1 billion in the US alone [11, 12] . While the treatment of VAF is relatively well-established (e.g., endovascular therapy and surgical reconstruction), little is known regarding the strategies for preventing VAF. In this study, we review the available literature on strategies for preventing VAF in HD with a focus on AVFs and AVGs.
Main text

Definition of VAF
The definitions of VAF vary slightly throughout the literature and published guidelines. In this review, VAF is defined in accordance with the indication of VA treatment recommended by JSDT guidelines. Accordingly, VA was indicated in more than 50% stenosis or thrombosis along with one or more of the following clinical medical abnormalities: (i) decreased blood flow (< 500 ml/min in AVFs or < 650 ml/min in AVGs), (ii) increased venous pressure, (iii) abnormally high blood urea nitrogen level, and (iv) unexplained reduction in dialysis efficiency [8] .
Risk factors of VAF
Several risk factors of VAF (Table 1) have been widely reported.
Age
Reportedly, the proportion of elderly patients > 65 years of age receiving RRT was 66%, 40%, and 42% in Japan (2016), the US (2016), and Europe (2015), respectively [10, 13, 14] . However, there are conflicting data on whether older age is a risk factor for AVF maturation. A recent review focusing on VA in elderly patients undergoing HD demonstrated that older age is one of the risk factors for AVF maturation failure [14, 15] . Moreover, a prospective study involving 176 patients revealed that elderly patients ≥ 65 years of age with diabetes exhibited a markedly increased risk of VAF [16] . In addition, a prospective study on 422 patients, aiming to identify patient profiles associated with the failure of AVF maturation, revealed that an age of ≥ 65 years was an independent risk factor of VAF [odds ratio (OR) 2.23; 95% confidence interval (95% CI), 1.25-3.96] [17] . In contrast, a multicenter prospective study on 395 patients undergoing HD demonstrated that an age of ≥ 65 years was not associated with the primary functional loss of AVF patency [hazard ratio (HR) 1.49, 95% CI 0.96-2.31] [18] . Further, a recent retrospective study on 525 patients who underwent AVF constructions and who were stratified by age (< 65, 65-75, and > 75 years) revealed that no significant differences in the incidence of primary VAF or primary patency after 1-3 years [19] . These findings suggested that VAF occurs frequently in elderly patients because the blood flow of AVF in the elderly was lower than that in non-elderly patients possibly due to atherosclerosis with aging [14, 15, 20] .
Sex
The role of sex as a risk factor of VAF is controversial. A multicenter prospective study on 395 patients undergoing HD revealed that sex was not associated with primary functional AVF patency loss (HR 1.52, 95% CI 0.99-2.34) [18] . However, several reports showed that female sex is one of the risk factors of VAF. According to the USRDS data in 2018, AVF maturation time was longer in females than that in males (128 vs. 116 days), and the rate of AVF maturation failure was higher in females than that in males (45.1% vs. 34.2%) [10] . Moreover, a retrospective study on 444 patients showed that males had a lower risk of VAF (HR 0.63, 95% CI 0.44-0.91) [21] . Similarly, another retrospective study on 205 patients showed that female sex was a significant risk factor of AVF maturation failure (HR 2.42, 95% CI 1.32-4.45) [22] . In addition, a prospective study involving 360 elderly patients undergoing HD (≥ 67 years) clearly demonstrated that female sex was associated with VAF (OR 1.69, 95% CI 1.55-1.83) [23] . Although the reasons for these differences based on sex have not been clarified, a review on VA noted that vessel diameter is generally smaller in females than that in males and that this difference may be associated with AVF maturation failure in females [24] .
Ethnicity
Race and ethnicity differences may be significant risk factors of AVF maturation failure. According to the USRDS 2018 data regarding race differences, black population had the highest rate of AVF maturation failure (42.0%). A recent retrospective study reported that the rate of AVF maturation failure was higher in non-Hispanics than that in Hispanics (39.7% vs. 33.8%) [10] . Although an observational study showed that the AVF adequacy rate was not influenced by patient race, other studies have demonstrated race or ethnicity as a risk factor of VAF or AVF maturation failure [17, 23, [25] [26] [27] [28] . These findings suggested racial or ethnic differences in the incidence rate of VAF. Here are some reasons to consider in racial differences such as racial differences in prevalence of arteriosclerosis [29] , gene expression differences regarding hypertension [30] , racial differences in oxidative stress and inflammation [31] or racial difference in endothelial function [32] .
Comorbid conditions
Clinical comorbidities such as coronary artery disease (CAD), peripheral arterial disease (PAD), diabetes mellitus, and obesity have been reported as risk factors of VAF in patients undergoing HD.
CAD In a retrospective study, 1618 patients undergoing HD in Taiwan were categorized into two groups: early (< 1 year) and late (> 1 year) loss of primary functional patency, based on intervention-free intervals. In an analysis of demographic and clinical characteristics, patients who exhibited an early loss of primary functional patency showed higher proportions of CAD (P = 0.02) [33] . A prospective study on 422 patients revealed that CAD was an independent risk factor for AVF maturation failure (OR 2.83, 95% CI 1.60-5.00) [17] . Interestingly, a recent study demonstrated that increasing the mean platelet volume (MPV)/platelet count ratio, previously identified as an independent predictor of 4-year mortality following myocardial infarction [34] , was useful for predicting VAF [35] .
PAD A review reported that the inflow artery was required to increase the baseline blood flow by 10-20 times as well as to deliver the necessary blood volume to AVF to ensure a functional AVF [36] . PAD can increase the risk of VAF by interfering with the increase in blood volume to AVF because arteries affected by PAD can fail to sufficiently dilate due to intimal hyperplasia and arterial calcification. An observational retrospective study on 784 incident patients undergoing HD showed that a history of PAD increased the risk of VAF by 24% [37] . Interestingly, a prospective study on 422 patients revealed that PAD was an independent risk factor of AVF maturation failure (OR 2.97, 95% CI 1.34-6.57) [17] . Furthermore, a retrospective study on 111 patients undergoing HD showed that an ankle-brachial index (ABI) of < 0.9 was significantly associated with VAF and that ABI could potentially identify patients at a high risk of VAF [38] .
Diabetes mellitus Patients' glycemic states should be evaluated before VA construction because glycemic state abnormality can cause wound infection or delayed wound healing. Moreover, diabetes mellitus is generally considered a risk factor of CVDs. However, several studies regarding VA have suggested that diabetic state alone does not affect VAF when adjusted for potential confounders, such as CAD, PAD, and obesity [16, [39] [40] [41] [42] .
Obesity According to the results of a retrospective cohort study that used the USRDS Dialysis Morbidity and Mortality Wave II dataset, obesity was associated with poor AVF maturation in patients in the highest body mass index (BMI) quartile (≥ 35 kg/m 2 ) (OR 3.66, 95% CI 1.27-10.55, P = 0.017) [42] . Furthermore, in another study on 183 AVFs comparing obese patients with non-obese patients, the likelihood of AVF construction and primary patency rates were almost equal between the groups. However, secondary patency rates of AVFs were significantly lower in obese patients (HR 2.93, 95% CI 1.44-5.93, P = 0.004) than those in non-obese patients (HR 1.13, 95% CI 0.42-3.06, P = 0.80) [43] . A case report suggested that in the adducted position, soft tissue compression of the venous outflow of the upper extremity causes reduced secondary patency that is observed in obese patients [44] .
Prevention of VAF
The prevention of VAF is crucial for all healthcare providers involved in RRT. This review proposed the prevention of VAF based on the following criteria: (i) preoperative examination, (ii) prophylactic drugs for VAF, and (iii) maintenance of VA by monitoring and surveillance.
Preoperative examination
Physical examination Physical examination of VA in patients undergoing HD is an essential skill that all healthcare providers directly directly involved in HD must inculcate. Before surgery, any history of any central venous catheters or pacemaker should be confirmed [45] . In addition, clinicians should carefully assess for signs of venous hypertension, such as prominent and tortuous collateral veins around the shoulder and upper limb edema, in the limb undergoing surgery. Particularly, obese patients typically exhibit a thick subcutaneous adipose tissue layer in their extremities; thus, VAF or AVF maturation failure can occur in such patients due to the venous depth. A salvage operation to retrieve the AVF could be useful in obese patients when AVF is located deep in the skin [46] . Alternatively, several studies have suggested that lipectomy or liposuction can prove useful to allow a functional AVF construction in obese arms [47] [48] [49] [50] .
Differential blood pressures To check for arterial stenosis, the difference in the blood pressures of the two upper arms can be useful because arterial inflow insufficiency is a risk factor of VAF or AVF maturation failure; this difference in blood pressures was suggested to be useful by a review [51] . According to the clinical guidelines of the Society for Vascular Surgery, arterial stenosis commonly occurs as an orifical stenosis of the subclavian artery caused by atherosclerosis. In addition, the guidelines recommend the patient should undergo access viability evaluation and risk stratification before undergoing arterial stenosis management.
Allen test The Allen test is used to evaluate the blood supply to the hand. The presence of adequately functioning dual circulation to the hand, which is represented by the radial and ulnar arteries that distally communicating through the palmar arches, is a crucial protective mechanism against hand ischemia. In addition, the use of pulse oximetry as an aid to the Allen test has been reported to provide added information regarding collateral hand circulation [52] .
Preoperative vascular imaging The low quality of the available vessels for VA construction is reportedly the most critical risk factor of VAF. Thus, preoperative arterial and venous evaluation, known as "vascular imaging," is crucial for predicting VAF or AVF maturation failure. JSDT guidelines recommend that an ultrasound examination is preferred to preoperatively evaluate vessels rather than to rely on physical examination alone [8] . Non-invasive ultrasound examination can provide detailed preoperative information regarding vascular qualities, vessel diameters, and vessel depth.
Arterial imaging Several studies have reported that the smallest diameter of the radial artery that is required for successful radiocephalic AVF construction is 1.5-2.0 mm [53] [54] [55] . However, arterial diameter is not the sole indicator of successful AVFs construction; wall thickness and function must be assessed during arterial evaluation. In the Hemodialysis Fistula Maturation Study, patients who were enrolled from seven clinical centers underwent up to five preoperative vascular function tests. As a result, increased nitroglycerin-mediated dilation or flow-mediated dilation was associated with significantly greater AVF blood flow rates and AVF diameters after 6 weeks. These findings illustrate the importance of evaluating the intrinsic ability of arterial dilation before AVF construction [56] .
Venous imaging The incidence of VAF is much higher in veins than that in arteries because of venipuncture required for each HD session. In addition, several studies reported structural abnormalities in patients with ESRD, regardless of AVF constructions [57, 58] .
Regarding veins, a clinical study demonstrated that a venous luminal diameter of ≥ 2.5 mm and of ≥ 4.0 mm is essential for AVF and AVG, respectively; additionally, the continuity of distal superficial veins in the forearm is essential [59] . Furthermore, several reports have emphasized the importance of evaluating vein distensibility before AVF construction [59] [60] [61] . Evaluating venous dilatation involves the inflation of the blood pressure cuff or the use of a tourniquet above the vein so that the vein can dilate at least 50% of the remaining inner diameter [61] .
Drugs for VAF prophylaxis
Several studies have investigated the effectiveness of drugs for VAF prophylaxis during the perioperative period; the drugs studies mainly include cardiovascular drugs such as antiplatelet drugs [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] , anticoagulant drugs [72] [73] [74] , statins [75] [76] [77] [78] [79] , fish oil [68, 80, 81] , and antihypertensive drugs [82] [83] [84] [85] .
Antiplatelet drugs As shown in Table 2 and Table 3 , the effect of antiplatelet drugs on VAF has been Table 2) . Regarding AVGs, the results of a multicenter study suggested that dipyridamole plus aspirin improved primary patency. In this study, 649 patients were randomly assigned to receive aspirin (25 mg twice daily) plus extended-release dipyridamole (200 mg twice daily) or placebo after AVG construction. The results showed that aspirin plus dipyridamole was associated with a modest but significant increase in the primary unassisted patency rates (HR 0.82, 95% CI 0.68-0.98, P = 0.03). Both groups demonstrated an equal incidence of adverse events (particularly bleeding), AVG failure, and death. Furthermore, the incidence of bleeding events in the aforementioned study associated with aspirin plus dipyridamole may have been lower than the anticipated incidence; however, patients at a high risk of bleeding were excluded from the study. Thus, this finding may have been biased [62] (Table 3) .
Clopidogrel The effect of clopidogrel on VAF has also been controversial. In a multicenter randomized study on 877 patients who received clopidogrel (300 mg load followed by 75 mg daily) before AVF construction showed reduced rates of early VAF due to thrombosis. However, clopidogrel did not affect the proportion of functional AVFs (61.8% vs. 59.5%; RR 1.05, 95% CI 0.94-1.17, P = 0.40) [70] (Table 2) .
Regarding AVGs, a prospective study on 19 patients showed that clopidogrel (75 mg daily) administered after AVG construction reduced the number of thrombotic episodes and prolonged the time to AVG failure (350 vs. 86 days, P < 0.001) [63] . However, a multicenter, randomized study on 200 patients evaluating the effectiveness of aspirin (325 mg daily) plus clopidogrel (75 mg daily) versus placebo in preventing AVG thrombosis after AVG construction demonstrated that aspirin plus clopidogrel did not prevent AVG thrombosis (HR 0.81, 95% CI 0.47-1.40, P = 0.45); however, whereas this treatment increased the frequency of bleeding events. The study was discontinued due to the doubled risk of bleeding among those receiving aspirin plus clopidogrel (HR 1.98, 95% CI 1.19-3.28) [64] ( Table 3) .
Ticlopidine The effect of ticlopidine on VAF could be limited. In a multicenter, randomized study on 258 patients, ticlopidine (250 mg twice daily) before AVF construction did not significantly reduce AVF thrombosis compared with placebo (12% vs. 19%; P = 0.101) [71] (Table 2) .
Cilostazol Cilostazol could be effective for the prevention of VAF on AVF. In a retrospective study on 149 patients, 33 received cilostazol for ≥ 30 days before AVF construction and continued cilostazol therapy for ≥ 60 days postoperatively. The matched control group Table 2) . Table 4 , the effect of anticoagulant drugs on VAF could be limited. In two randomized studies, systemic anticoagulation therapy, comprising 5000 IU of intravenous heparin administered during before AVF construction was associated with no benefit regarding AVF patency. However, there were significantly more bleeding events in the heparin group than those in the non-heparin group [72, 73] . A randomized trial of 115 patients demonstrated that systemic anticoagulation therapy, comprising 5000 IU of intravenous heparin administered during the perioperative stage of AVG construction could not prevent AVG thrombosis. Interestingly, the use of systemic anticoagulation therapy was associated with an increased risk of bleeding events [72] . In addition, a multicenter clinical study, in which 107 patients were randomly assigned to receive either low-intensity warfarin [target international normalized ratio, (INR) 1.5-1.9] or placebo after AVG construction, revealed that there was no difference in the time to VAF between the two groups (199 vs. 83 days, P = NS). However, more bleeding events were noted in the warfarin group than those in the placebo group. Surprisingly, despite close INR monitoring, 10% of patients in the warfarin group developed major hemorrhage events [74] .
Anticoagulant drugs As shown in
Statins As shown in Table 5 , the effect of statins on VAF has been controversial. the SHARP trial (Study of Heart and Renal Protection), the AURORA study (A In the SHARP trial, 9270 patients with chronic kidney disease were randomly assigned to receive either simvastatin (20 mg) and ezetimibe (10 mg) or placebo before AVF construction; the results of this trial suggested that compared with placebo, lowering low-density lipoprotein cholesterol with statins improves VA patency (33.5% vs. 29.7%; RR 0.87, 95% CI 0.75-1.00, P = 0.05) [76] . To further investigate the hypothesis suggested by the SHARP trial, a combined analysis of data from the SHARP and AUR-ORA trials was performed. After combining the two trials, the overall effect on VAF events, following the reduction of low-density lipoprotein cholesterol with a statin-based regimen, was not statistically significant (29.3% vs. 30.5%; RR 0.95, 95% CI 0.85-1.05, P = 0.29) [75] .
In the AURORA trial, 2776 patients were randomly assigned to receive either rosuvastatin (10 mg) or placebo before AVF construction; the results demonstrated that statin treatment did not influence VA (RR 1.10, 95% CI 0.95-1.27, P = 0.19) [78] .
In 2005, a large randomized controlled trial (n = 1255) evaluating the efficacy and safety of atorvastatin in patients with type 2 diabetes undergoing HD (4D Study) [79] revealed that atorvastatin had no significant beneficial effect on the primary end-points such as cardiovascular death, nonfatal myocardial infarction, and stroke. However, the efficacy of atorvastatin for the prevention of VAF was not assessed in this trial or related sub-group analyses.
Fish oil As shown in Table 6 , the effect of fish oil on VAF has been controversial. A multicenter, randomized controlled study involving 567 patients who received 4 g of fish oil or placebo every day prior to AVF construction demonstrated no significant difference in the incidence of VAF after 12 months between the two groups (22% vs. 23%; RR 0.98, 95% CI 0.72-1.34, P = 0.90). In addition, secondary outcomes such as thrombosis, the abandonment of AVF, and cannulation failure did not significantly differ between the two groups [68] . Conversely, a multicenter, randomized controlled trial on 201 patients who received 4 g of fish oil or placebo daily before AVG construction demonstrated that fish oil reduced the rate of AVG failure (3.43% vs. 5.95%; HR 0.58, 95% CI 0.44-0.75, P < 0.001). In addition, secondary outcomes such as thrombosis (3.41% vs. 1.71%) and VA intervention (4.92% vs. 2.89%) were lower in the fish oil group than those in the placebo group [80] .
Antihypertensive drugs As shown in Table 7 , reninangiotensin system inhibitors (RAS-I) could be useful for the prevention of VAF. several studies evaluated the effects of antihypertensive drugs, such as reninangiotensin system inhibitors (RAS-I), on VAF. A large retrospective study enrolled 42,244 patients (AVFs 89.4%, AVGs 10.6%) to determine the effects of antihypertensive drugs on long-term VA patency. In this study, angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB) were eligible for analysis owing to their cardioprotective effects. The results of the aforementioned study showed that the use of ACE-I, ARB, and CCB were associated with prolonged primary AVF patency (HR 0.586, 0.532, and 0.485 for ACE-I, ARB, and CCB, respectively) and AVGs (HR 0.557, 0.536, and 0.482 for ACE-I, ARB, and CCB, respectively) [82] . These results indicated that RAS-I can be useful for the prevention of VAF.
However, a secondary analysis of data from the HEMO (Effect of dialysis dose and membrane flux in maintenance hemodialysis) study [87] demonstrated an association between an increased risk of VAF and VAF vascular access failure, VA vascular access, AVF arteriovenous fistula, AVG arteriovenous graft, RR relative risk, HR hazard ratio, CI confidential interval, Pre preoperative period, Post post-operative period frequent episodes of intradialytic hypotension and lower predialysis systolic blood pressure [88] .
Maintenance of VA
Maintenance of VA plays an important role for preventing VAF after VA construction. According to various guidelines, in particular, blood pressure management during HD, monitoring, and surveillance, which we review and focus on these points in this chapter, are important.
Blood pressure management
JSDT guidelines suggest that hypotension is one of risk factors of VA occlusion [8] , and several studies indicated the association between hypotension and VAF. A secondary analysis of data from the HEMO study aiming to identify risk factors of VAF was performed [88] . This study examined whether frequent episodes of hypotension and blood pressure fluctuation during HD were associated with VAF 1426 patients undergoing HD. In AVFs, patients undergoing HD with frequent episodes of intradialytic hypotension had a higher incidence of AVF thrombosis (RR 2.02, 95% CI 1.22-3.35, P < 0.01). Whereas in AVGs, patients undergoing HD with higher predialysis systolic blood pressure had a lower incidence of AVG thrombosis (RR 0.88, 95% CI 0.80-0.97, P < 0.01) [88] .
An observational study enrolled 463 patients undergoing HD to examine the risk factors affecting AVF patency during 5 years of follow-up. In this study, patients with early AVF failure were excluded from the analysis (P = 0.002). Episodes of hypotension were defined as systolic pressure of < 110 mmHg and diastolic pressure of < 70 mmHg before the start of HD. In patients with hypertension, a decrease by > 30% of blood pressure was defined as relative hypotension. During ten consecutive HD sessions, 218 patients experienced at least one episode of hypotension. This study demonstrated that the lowest mean diastolic pressure had significantly lower patency rates of AVF (P = 0.045) than that of the mean diastolic pressure, whereas the lowest mean systolic pressure had no effect (P = 0.624) [89] . Considering that blood pressure fluctuation during HD was associated with VAF, appropriate blood pressure management during HD could be crucial for prevention of VAF.
Monitoring and surveillance
As shown in Table 8 , several guidelines recommend both monitoring and surveillance to facilitate the early detection of VAF after VA construction [8, 10, 15] .
Vascular access nurse VA nurses, also called VA coordinators or VA managers, play a crucial role in the prevention of VAF. As shown in Table 9 , they have various responsibilities to manage VA and prevent Table 8 Monitoring and surveillance for VAF [90, 91] . Furthermore, an observational study of 450 HD patients revealed that VA coordinators could markedly reduce surgical complications during AVG construction by 14% and decrease the incidence of AVG thrombosis by 60% [92] .
Monitoring Physical examinations are useful for early detection of VAF. Three components for VA examination are recommended by guidelines: inspection, palpation, and auscultation [8, 10, 15] . Abnormalities of physical examination, such as extremity edema, alterations in the pulse, thrill, or bruit, may be associated with impending VAF.
On the other hand, ultrasound examination is a non-invasive and effective apparatus that provides beneficial information for the monitoring of VA, as well as a tool for preoperative vascular imaging. In particular, blood flow of VA was estimated by measuring the brachial artery volume flow using ultrasound examination. VAF should be suspected when blood flow is less than 500 ml/min (JDST, ESVS) or less than 400-500 ml/min (K/DOQI) in AVFs [8, 10, 15], although there is no clear definition of maturation. Besides, an observational study of 101 AVFs was performed to evaluate the association between adequate AVF rates and risk factors of VAF. In this study, AVF was defined as adequate for HD when the AVF was successfully cannulated over a period of at least six HD sessions in a month, and AVF was required a blood flow of at least a consistent 350 ml/min [28] . This study was cited in ESVS guidelines; this guidelines suggest that cannulation of VA is not preferred when the quantity of blood flow is less than 350 ml/min, although the levels of evidence are not high [15] .
Surveillance at frequent stenotic site As shown in Fig. 1 , the highest incidence of AVF stenosis was noted within 3 cm of the anastomosis site [93] . VAF due to stenosis or thrombosis is more commonly associated with AVG than with AVF. A randomized, double-blind, placebo-controlled trial revealed that > 90% of thrombosed AVGs exhibited a stenotic lesion [62] . In AVGs, stenosis most commonly occurred in the outflow vessel of the access, i.e., the site of venous anastomosis. As shown in Fig. 2 , a retrospective observational study revealed that 47% of AVG stenosis occurred at the site of venous anastomosis, and 11% occurred within 1 cm of the anastomosis site in a typical looped-upper arm AVG [94] .
Conclusions
In this review, we summarized the available literatures regarding the prevention of VAF in patients with HD with a focus on AVFs and AVGs. As shown in Fig. 3 , this review supports the use of the following three aspects for developing strategies for preventing VAF: (i) early identification of risk factors of VAF (e.g., preoperative vascular conditions, age, sex, ethnicity, and clinical backgrounds), (ii) prophylactic drugs to reduce the risk of VAF, and (iii) early VAF detection through monitoring and surveillance of VA, particularly at frequent stenotic sites. In particular, some prophylactic drugs may be effective for the prevention of VAF based on the patient's clinical background or the type of VA used. However, there are no prophylactic drugs that can be potentially used for reducing the incidence of VAF. Therefore, further large, randomized placebo-controlled studies are warranted to support the development of effective strategies for preventing VAF. Although there have been no reports of prophylactic drugs with strong efficacy for preventing VAF, such drugs could be effective in any phase. Either VAIVT or surgical reconstruction must be selected when VAF occurs. Particularly, surgical reconstruction in a proximal region could be possible, especially if VAF occurs as a result of thrombotic occlusion. Surgical reconstruction implies the relocation of the anastomosis to a proximal site
